Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00668642 · ClinicalTrials.gov registry record · Phase 2
Effect of Dutasteride on Androgen-Response Gene Expression in Patients With Advanced Prostate Cancer
A Phase 2 study, sponsored by Endeavor Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT00668642 is a Phase 2 study that has completed, run by Endeavor Health. The registered enrollment target is 20 participants.
The verdict
NCT00668642, a Phase 2 study, has completed, sponsored by Endeavor Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the drug dutasteride increases expression of genes that slow the growth of prostate cancer during treatment with intermittent androgen ablation therapy (hormone therapy).
Interventions
- DRUG Placebo
- DRUG Dutasteride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2007-03 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00668642
The ClinicalTrials.gov registry entry for NCT00668642 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endeavor Health, which has 94 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00668642 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00668642 about?
NCT00668642 is a clinical study titled "Effect of Dutasteride on Androgen-Response Gene Expression in Patients With Advanced Prostate Cancer". The purpose of this study is to determine if the drug dutasteride increases expression of genes that slow the growth of prostate cancer during treatment with intermittent androgen ablation therapy (hormone therapy).
What is the current status of trial NCT00668642?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2007-03. Estimated completion is 2013-05.
What interventions are being tested in trial NCT00668642?
The interventions under investigation include: Placebo (DRUG), Dutasteride (DRUG).
Who is sponsoring clinical trial NCT00668642?
This trial is sponsored by Endeavor Health, which has 94 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.